Alpha Briefing
$SLS Gains 156% on a Phase 3 Leukemia Vaccine Win, Then Files a $150 Million Offering Overnight: The REGAL Fine Print, the Dilution Math, and the Zones From $10 to $35
Paid-members only
Markets Featured

$SLS Gains 156% on a Phase 3 Leukemia Vaccine Win, Then Files a $150 Million Offering Overnight: The REGAL Fine Print, the Dilution Math, and the Zones From $10 to $35

SELLAS's cancer vaccine cut death risk 41% in Phase 3 AML (median survival 24.0 vs 14.7 months), sending the stock from $7.47 to $19.15 — then management filed a $150M offering after hours. The pro-forma cash math, the three things the headline glosses over, and the scenario zones from $10 to $35.
9 min read
$RCAT Loses a Third Overnight After Pulling Its 2026 Target: The $150 Million Promise vs. $47 Million Booked, the Gauntlet II Snub, and the Zones From $1.40 to $7
Paid-members only
Markets Featured

$RCAT Loses a Third Overnight After Pulling Its 2026 Target: The $150 Million Promise vs. $47 Million Booked, the Gauntlet II Snub, and the Zones From $1.40 to $7

Red Cat withdrew its $150-180M revenue target after a $11.8M Q3 against a ~$39M consensus, and named the Pentagon's Gauntlet II outcome as the reason. But at $2.39 premarket the enterprise value is ~$124M against $242.7M cash. The cash clock, the dilution record, and the zones from $1.40 to $7.
8 min read
Operated by veterans. Driven by discipline. Built for the early mover.
AlphaBriefing provides financial commentary and market analysis for informational purposes only. We do not offer personalized investment advice. All content is opinion-based and should not be considered a recommendation to buy or sell any security. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. Individual results may vary. We value your privacy. Any data collected is used to improve your experience and to provide relevant updates about our services.
©2025 AlphaBriefing. All rights reserved. | Privacy Policy | Legal Disclaimer